Next-generation sequencing could be a powerful and independent predictor for relapse and survival among adults with acute myeloid leukemia.
The FDA approved bosutinib (Bosulif) for use as a treatment of patients with newly diagnosed chronic-phase Philadelphia chromosome–positive chronic myeloid leukemia.
A recent analysis from the Breast Cancer Surveillance Consortium revealed that community oncology practices are neglecting to use MRI screening for at-risk women, and lower-risk women are being unnecessarily screened.
Adding rituximab to MBVP induction chemotherapy does not improve outcomes for patients with primary central nervous system lymphoma.
Patient access to NCI Cancer Centers is influenced by a complex mix of cancer center distribution and density, ethnicity, urbanicity, and travel time to care, according to a recently published statistical model.
Rolapitant plus 5-HT3 receptor antagonist and dexamethasone is well tolerated and more effectively controls chemotherapy-induced nausea and vomiting compared with 5-HT3 and dexamethasone alone.
Researchers have discovered that testicular cancer’s responsiveness to conventional chemotherapy is likely determined during prenatal development.
Adding daratumumab to either of two standard-of-care treatment regimens induces rapid, deep, and durable responses and improves progression-free survival in patients with relapsed/refractory multiple myeloma, confirm updated findings from the open-label phase III POLLUX and CASTOR trials.
An investigational antibody-drug conjugate that targets a key B-cell maturation antigen, offers “deep and durable” responses to some patients with relapsed/refractory multiple myeloma, suggest preliminary findings from the expansion part of the phase I DREAMM-1 trial.
Researchers found that combining palonosetron, aprepitant, and dexamethasone represents an effective and well-tolerated treatment to prevent CINV in testicular cancer patients receiving cisplatin.